Latest Breaking News On - Molecular therapeutic - Page 13 : comparemela.com

Financial Review: 4D Molecular Therapeutics (FDMT) vs Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) is one of 264 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare 4D Molecular Therapeutics to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations. Institutional & […]

United statesD molecular therapeutics incMolecular therapeuticsGet ratingMolecular therapeutic4d molecular therapeuticsNasdaq fdmtStock comparisonStock analysis

4D Molecular Therapeutics (NASDAQ:FDMT) and Axcella Health (NASDAQ:AXLA) Head to Head Survey

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) and Axcella Health (NASDAQ:AXLA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 76.6% of 4D Molecular […]

United statesUnited kingdomAxcella health incD molecular therapeutics company profile get ratingAxcella healthAxcella health company profile get ratingD molecular therapeutics incMolecular therapeuticsGet ratingMolecular therapeuticMolecular therapeutics company profileHealth company profile4d molecular therapeuticsNasdaq fdmtStock comparisonStock analysis

DBV Technologies (NASDAQ:DBVT) & 4D Molecular Therapeutics (NASDAQ:FDMT) Head-To-Head Analysis

DBV Technologies (NASDAQ:DBVT – Get Rating) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability. Valuation and Earnings This table compares DBV Technologies […]

France generalUnited statesD molecular therapeutics company profile get ratingTechnologies company profile get ratingHealth scienceD molecular therapeutics incGet ratingMolecular therapeuticsMolecular therapeuticCompany profileViaskin peanutViaskin milkViaskin eggMolecular therapeutics company profileDbv technologiesNasdaq dbvt

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary. | March 28, 2022

United statesIngrid mezoMike zanoniDavid kirnExchange commissionCanale communicationsDrug administrationD molecular therapeutics incGlobenewswire incMolecular therapeuticsTherapeutic vector evolutionChief executive officerNew drugMarketable securitiesPrivate securities litigation reform actMolecular therapeutic

FDA Grants Fast Track Designation to 4D Molecular Therapeutics for Retinitis Pigmentosa Therapy

FDA Grants Fast Track Designation to 4D Molecular Therapeutics for Retinitis Pigmentosa Therapy
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRobert kimDrug administrationFast trackMolecular therapeuticOphthalmology therapeutic area